MPF, or maturation-promoting factor, is the master switch that pushes cells into division. It is a protein complex made of two parts: a kinase called CDK1 and its partner cyclin B. When active, MPF triggers the dramatic physical changes of mitosis, from chromosome compaction to the breakdown of the nuclear envelope. The story of how this complex was discovered, how it flips on and off with precise timing, and what goes wrong when it misbehaves in disease turns out to be one of the more elegant chapters in cell biology.
How MPF Was Discovered
The concept of MPF came out of frog egg experiments in the 1970s and 1980s. Researchers found that when they injected cytoplasm from a dividing frog cell into an immature oocyte (an egg cell stuck in a resting state), the oocyte suddenly matured and entered meiosis. Something in that cytoplasm was forcing the transition, and they named it maturation-promoting factor. Later work showed that MPF was not limited to frogs. It could be detected in dividing cells across a huge range of species, from yeast to human cells. In a landmark set of experiments, researchers demonstrated that simply adding and removing MPF could drive the entire mitotic cycle in frog eggs without any new protein being made, producing nuclear envelope breakdown and reformation, chromosome condensation and decondensation, and controlled rounds of DNA replication.1PubMed. Regulation of the cell cycle during early Xenopus development The implication was striking: a single biochemical activity could orchestrate the whole process of cell division.
What MPF Is Made Of
It took years of biochemical purification to figure out that MPF consists of two proteins bound together. The catalytic half is CDK1 (also called Cdc2 in older literature), a cyclin-dependent kinase. On its own, CDK1 is essentially inert. It only becomes an active enzyme when it binds to its regulatory partner, cyclin B. Crystal structures of the CDK1–cyclin B complex confirm that cyclin binding remodels the shape of CDK1 in ways that open up its active site, much as it does in related kinases.2PubMed Central. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK The same structural work showed that, compared with closely related kinase complexes, CDK1–cyclin B is less thermally stable and has a smaller contact surface between the two proteins. That built-in fragility turns out to be functionally useful: it makes the complex easier to disassemble rapidly when it is time to exit mitosis.
The Activation Switch
Cells do not simply let MPF turn on whenever cyclin B shows up. A multi-layered system of brakes ensures that full activation happens only at the right moment. Once cyclin B binds CDK1, another kinase called CAK phosphorylates a residue on CDK1 (threonine-161) that locks the two proteins together and arranges the active site into a working configuration.3PubMed Central. Quantitative Reconstitution of Mitotic CDK1 Activation in Somatic Cell Extracts But almost immediately, two inhibitory kinases, WEE1 and MYT1, slap phosphate groups onto two other residues on CDK1 (threonine-14 and tyrosine-15), blocking its ability to use ATP and keeping it shut down. The result is a stockpile of “pre-loaded” MPF that is assembled but silenced.
The cell crosses the threshold into mitosis when a phosphatase called Cdc25 strips away those inhibitory phosphates faster than WEE1 and MYT1 can add them back. This is where the system gets interesting: active MPF itself stimulates Cdc25 while also inhibiting WEE1. That creates a positive feedback loop, a biochemical chain reaction in which a small initial burst of MPF activity rapidly amplifies itself into full activation.4PubMed. Phosphatase 2A and polo kinase, two antagonistic regulators of cdc25 activation and MPF auto-amplification The switch-like quality of this loop explains why entry into mitosis is so abrupt. Cells do not gradually slide into division; they snap into it once the feedback loop fires.
What happens when that braking system is removed prematurely? Experiments using mutant forms of CDK1 that cannot be phosphorylated by WEE1 showed that CDK1 activity shot up during S phase, long before the cell was ready for division. The mutant cells exhibited elevated CDK1-associated kinase activity as early as 16 hours into the cell cycle, peaking well ahead of schedule despite low cyclin B levels, because without the inhibitory phosphorylation, CDK1 was activated the instant any cyclin bound to it.5Oncogene. Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality The consequences were lethal in developing embryos, confirming that precise timing of MPF activation is not optional.
A kinase called Greatwall adds another layer to this system. Once activated by MPF, Greatwall participates in an autoregulatory loop that helps sustain high MPF activity during mitosis, partly by blocking the phosphatases that would otherwise counteract MPF’s effects on its targets.6PubMed Central. Roles of Greatwall kinase in the regulation of cdc25 phosphatase
Getting to the Right Place at the Right Time
Activation alone is not enough. MPF also has to be in the right compartment of the cell. During most of the cell cycle, the CDK1–cyclin B1 complex sits predominantly in the cytoplasm. At the end of G2 phase, just before division begins, the complex is rapidly imported into the nucleus.7PubMed. Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta This nuclear translocation is tightly coupled to the activation of the complex, and it gives MPF direct access to its nuclear targets, including the chromosomes and the nuclear lamina. Forcing cyclin B1 into the nucleus prematurely can override certain checkpoints and push cells into mitosis early, which underlines how spatial control serves as an independent safety mechanism on top of the biochemical switch.8PubMed Central. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage
What MPF Actually Does Once Active
Active MPF is a kinase, meaning it works by attaching phosphate groups to other proteins. The list of its targets reads like a to-do list for disassembling and reorganizing the cell in preparation for division. Several of the most important downstream effects are well characterized.
The nuclear envelope is held together by a meshwork of structural proteins called lamins. MPF phosphorylates lamins A, B, and C on specific sites, which causes the filaments to fall apart and the nuclear envelope to break down.9PubMed. Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis Classic experiments showed that adding MPF to lamin filaments assembled in a test tube caused them to disassemble in direct proportion to phosphorylation at those sites.10PubMed. Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C Without nuclear envelope breakdown, the mitotic spindle cannot access the chromosomes, so this is one of the earliest and most essential tasks MPF performs.
Chromosomes also need to compact from their loose interphase state into the tight, rod-shaped structures visible under a microscope. MPF contributes to this by phosphorylating a subunit of the condensin II complex, which is one of the protein machines that physically compresses DNA. CDK1-mediated phosphorylation of the CAP-D3 subunit of condensin II creates a docking site for another kinase, Plk1, which then further phosphorylates the complex to drive timely chromosome condensation during prophase.11PubMed Central. The initial phase of chromosome condensation requires Cdk1-mediated phosphorylation of the CAP-D3 subunit of condensin II
MPF’s reach extends beyond the nucleus. The Golgi apparatus, a stack of membrane compartments involved in protein processing, fragments into small vesicles during mitosis so that each daughter cell can inherit a share. CDK1 phosphorylates a Golgi protein called GM130, which blocks it from binding a vesicle-docking partner. This inhibition shuts down normal membrane traffic through the Golgi and leads to its progressive fragmentation.12Cell. Mitotic Golgi Fragmentation and Regulation of GM130 by Cdc2 The mitotic spindle itself is another target: CDK1–cyclin B1 phosphorylates microtubule-associated proteins, and disrupting one of those phosphorylation events leads to a noticeable increase in abnormal bipolar spindles with disorganized or asymmetric shapes.13ASBMB Journal of Biological Chemistry. Cdk1-cyclin B1-mediated phosphorylation of tumor-associated microtubule-associated protein/cytoskeleton-associated protein 2 in mitosis
How MPF Is Shut Down
Getting into mitosis is only half the problem. The cell also has to get out cleanly, and that means dismantling MPF at the right moment. The exit strategy centers on destroying cyclin B. A large protein complex called the anaphase-promoting complex (APC/C) tags cyclin B with a molecular disposal signal (ubiquitin chains), marking it for rapid degradation. Once cyclin B is gone, CDK1 loses its activating partner and shuts off.14PubMed. Regulation of the cyclin B degradation system by an inhibitor of mitotic proteolysis
The timing of this destruction is controlled by the spindle assembly checkpoint (SAC), a surveillance system that monitors whether all chromosomes are properly attached to the spindle. As long as unattached chromosomes remain, the SAC holds APC/C in check, protecting cyclin B1 from premature destruction. The SAC itself depends on CDK1 activity to function, which creates an elegant self-limiting circuit: once the checkpoint is satisfied and APC/C begins degrading cyclin B, the resulting drop in CDK1 activity further weakens the checkpoint, accelerating cyclin B destruction and making the exit from mitosis irreversible.15Current Biology. Dependency of the Spindle Assembly Checkpoint on Cdk1 Renders the Anaphase Transition Irreversible Different cyclins are degraded on slightly different schedules: cyclin A2 is destroyed even while the SAC is active, whereas cyclin B1 is protected until all chromosomes are properly attached.16Nature Communications. Cyclin A2 degradation during the spindle assembly checkpoint requires multiple binding modes to the APC/C
MPF in Meiosis and Egg Arrest
MPF was originally discovered in the context of meiosis, and it plays a specialized role there that differs from its mitotic function. In vertebrate eggs, meiosis pauses at metaphase II while the egg waits for fertilization. This arrest is maintained by a system called cytostatic factor (CSF), which works by preventing cyclin B from being destroyed, thereby keeping MPF locked in its active state.17PubMed Central. How eggs arrest at metaphase II: MPF stabilisation plus APC/C inhibition equals Cytostatic Factor When a sperm fuses with the egg, it triggers a calcium wave that inactivates CSF, allows cyclin B degradation, and releases the egg from arrest so that development can begin. If this system fails, the egg either never arrests properly or cannot resume division after fertilization, both of which are fatal for embryonic development.
The DNA Damage Connection
Before a cell commits to division, it runs quality checks on its DNA. If damage is detected during S phase or G2 phase, checkpoint kinases activate a signaling cascade that converges on MPF. The checkpoint works by activating the inhibitory kinases that keep CDK1 phosphorylated and by excluding the CDK1–cyclin B1 complex from the nucleus, thereby delaying mitotic entry until repairs are complete.18ScienceDirect (Journal of Theoretical Biology). A predictive mathematical model of the DNA damage G2 checkpoint The spatial and biochemical controls on MPF reinforce each other here: even if some active CDK1 escapes the inhibitory phosphorylation, keeping it out of the nucleus prevents it from reaching its targets. Cells that override this checkpoint, whether through mutation or experimental manipulation, enter mitosis with broken chromosomes and typically die or produce dangerously unstable daughter cells.
When MPF Goes Wrong in Cancer
Given MPF’s central role in pushing cells through division, it is unsurprising that its components are frequently altered in cancer. A pan-cancer analysis found that cyclin B1 (the gene CCNB1) was significantly overexpressed in 23 different cancer types compared with normal tissues, including common malignancies like breast, lung, liver, and colon cancer. Higher cyclin B1 expression was also linked to more advanced tumor stages in multiple cancer types and to worse survival outcomes in lung, kidney, and liver cancers.19Scientific Reports. A pancancer analysis of the oncogenic role of cyclin B1 (CCNB1) in human tumors Overproduction of cyclin B1 can shorten the window during which checkpoints have time to act, effectively pushing cells past the quality-control gates before they can catch errors.
CDK1 itself is harder to target therapeutically than you might expect. Unlike some related kinases, CDK1 can compensate for the loss of other CDKs in the cell cycle, making it essential for normal dividing tissues as well as tumors. There are currently no FDA-approved drugs that selectively inhibit CDK1, though researchers are actively screening for candidates. Recent computational and biochemical work has identified a few compounds with sub-5 micromolar inhibitory activity against CDK1, but these remain in early preclinical stages.20ACS Omega. Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity
One promising clinical angle involves using broader CDK1/2 inhibitors in combination with other targeted therapies. In colorectal cancer models carrying a specific BRAF mutation, tumors that became resistant to standard BRAF and EGFR inhibitors showed upregulation of CDK1/2 and related cell-cycle checkpoint proteins. Adding dinaciclib, a CDK1/2 inhibitor, to the existing drug combination produced significant and durable tumor suppression across multiple mouse models, including outright tumor regression in some cases over nine weeks of treatment.21Cancer Research. Targeting CDK1/2-driven mechanisms of resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal cancer restores therapeutic response The challenge for drug development is selectivity: hitting CDK1 hard enough to kill tumor cells without crippling normal tissues that also depend on it for division.
An Ancient and Conserved Machine
The CDK1-based cell-cycle control system is remarkably old. Phylogenetic analyses suggest that CDK1, along with its key regulators WEE1 and Cdc25, was already present in the last eukaryotic common ancestor, meaning this machinery has been in continuous use since before animals, plants, and fungi diverged from one another. The checkpoint kinase Chk2 also appears to date back to that ancestor, while Chk1 emerged somewhat later. These core components have been retained across most eukaryotic lineages, though plants lost Cdc25 and Chk2 at some point, presumably evolving alternative mechanisms to fill those roles.22Scientific Reports. Evolution of opposing regulatory interactions underlies the emergence of eukaryotic cell cycle checkpoints The deep conservation of the CDK1 switch underscores why findings from frog eggs and yeast in the 1980s turned out to be directly relevant to human cancer biology decades later. The fundamental logic of MPF, build the kinase up, hold it in check, then release it in one sharp burst, has been working for over a billion years.